PSL bringing leading edge synthesis offering to IOPC oligo and peptide conference in Milan

Heidelberg, Germany: – Custom and modified peptide specialist Peptide Specialty Laboratories GmbH (PSL) will be an active presence at the third International Oligonucleotide and Peptide Conference, IOPC 2022, in Milan, Italy.

PSL will be represented in Milan at the late-June conference by its Head of R&D, Dr. Kerstin Wallraven, who will be taking part in the conference’s networking sessions.

Leading edge capabilities

Dr. Wallraven will be ready to talk to prospective partners about opportunities to leverage from the company’s extensive portfolio of capabilities.

These include leading-edge parallel and microwave-assisted peptide synthesis, as well as PSL’s specially developed continuous-flow synthesizer platform.

Customized peptide synthesis

“I’m really looking forward to attending this valuable conference,” said Kerstin Wallraven.

“IOPC attracts a very expert audience and I think there will be many there who want to talk about our offerings in customized peptide synthesis and end-to-end development of specific antibodies,” she said.

“It will also be a great opportunity to exchange knowledge with our peers on latest developments in the very dynamic fields of peptides and oligomers”, Kerstin added.

About PSL

Heidelberg-based Peptide Specialty Laboratories (PSL) specializes in synthesizing custom peptides, modified peptides as peptidomimetics and tailor-made peptide-specific antibodies.

PSL’s core expertise is in developing customized peptides varying in length up to 100 amino acids, individualized to customer requirements. These peptides can be further modified with modified amino acids (methylated, phosphorylated, sugar-modified, D-amino acids, stable isotopes etc.) through acetylation, placing amide at C-terminus and using peptide-protein conjugates (KLH, OVA, BSA, Diphtheria toxoid).

The laboratory develops and produces a range of customized synthetic peptides, bio conjugates and peptide-specific antibodies for research institutes, universities and pharma companies. It also synthesizes peptides as substrates for enzymes or performs modifications of peptides with specific properties that cannot be created naturally, mainly for use in drug research and also to produce complete immunization services.

Founded in 2000, PSL is a private-owned company. Further information at: https://www.peptid.de/en/homepage/

About IOPC 2022

First staged in 2019, the International Oligonucleotides and Peptides Conference (IOPC) was founded to provide a specialized annual knowledge sharing platform for Tides-based therapeutics.

The conference aims to help development and production practitioners optimize their oligonucleotide and peptide therapeutics value chains by following best practices and sharing  case studies.

IOPC 2022 is a three-day event opening June 27 at the Grand Visconti Palace, Milano.

One of the parallel scientific tracks will focus on Peptides, highlighting manufacturing upstream, purification, drug discovery, alternative applications, drug delivery and formulation, and materials. The other track will be devoted to Oligonucleotides, focusing on  chemical diversity and synthetic issues, delivery and formulation, preclinical studies, and clinical updates.

The event is organized by Tekno Scienze Srl, with further information at: https://www.iopc-tks.com/

Resources

Click on PSL Custom Peptides for further information.
Click on PSL Polyclonal Antibodies  for further information.